医药前沿
醫藥前沿
의약전연
YIAYAO QIANYAN
2015年
18期
137-138
,共2页
杨小涛%王艳春%杨震%陈后余
楊小濤%王豔春%楊震%陳後餘
양소도%왕염춘%양진%진후여
麻疹肺炎%肺炎支原体感染%临床治疗
痳疹肺炎%肺炎支原體感染%臨床治療
마진폐염%폐염지원체감염%림상치료
Measles pneumonia%Mycoplasma pneumoniae infection%Clinic treatment
目的:探讨麻疹肺炎合并肺炎支原体感染的临床特点,为临床诊治提供依据。方法:采用回顾性分析的方法对我院2012年10月至2015年2月收治的符合麻疹并肺炎的465例病例中合并肺炎支原体感染的31例患儿相关信息分析。结果:31例病例中30人治愈出院,1人好转后家属签字出院。3例予呼吸机辅助通气、1例有上机指针家长签字未上机治疗后好转出院。住院天数8-29天(平均11.3天)结论:麻疹肺炎合并肺炎支原体感染的患儿临床表现较为严重、易致呼吸衰竭甚至呼吸窘迫,早期予大环内酯类抗菌素联合三代头孢菌素、静脉丙球、甲强龙可取得满意疗效。
目的:探討痳疹肺炎閤併肺炎支原體感染的臨床特點,為臨床診治提供依據。方法:採用迴顧性分析的方法對我院2012年10月至2015年2月收治的符閤痳疹併肺炎的465例病例中閤併肺炎支原體感染的31例患兒相關信息分析。結果:31例病例中30人治愈齣院,1人好轉後傢屬籤字齣院。3例予呼吸機輔助通氣、1例有上機指針傢長籤字未上機治療後好轉齣院。住院天數8-29天(平均11.3天)結論:痳疹肺炎閤併肺炎支原體感染的患兒臨床錶現較為嚴重、易緻呼吸衰竭甚至呼吸窘迫,早期予大環內酯類抗菌素聯閤三代頭孢菌素、靜脈丙毬、甲彊龍可取得滿意療效。
목적:탐토마진폐염합병폐염지원체감염적림상특점,위림상진치제공의거。방법:채용회고성분석적방법대아원2012년10월지2015년2월수치적부합마진병폐염적465례병례중합병폐염지원체감염적31례환인상관신식분석。결과:31례병례중30인치유출원,1인호전후가속첨자출원。3례여호흡궤보조통기、1례유상궤지침가장첨자미상궤치료후호전출원。주원천수8-29천(평균11.3천)결론:마진폐염합병폐염지원체감염적환인림상표현교위엄중、역치호흡쇠갈심지호흡군박,조기여대배내지류항균소연합삼대두포균소、정맥병구、갑강룡가취득만의료효。
Objective To explore the clinical characteristics of measles pneumonia complicated by pneumonia myco plasma infection, providing the basis for the clinical diagnosis and treatment. Methods Retrospective analysis of 31 ca ses complicated by pneumonia mycoplasma infection in 465 cases with measles pneumonia admitted to our hospital fr om October 2012 to February 2015 was made. Results 30 people in 31 cases were cured and discharged from hospital , and 1 discharged with family sign when getting better. 3 cases were given the respirator to assist ventilation, and 1 wh o was supposed to but not accepted a respirator with family sign took a turn for the better and discharged. Hospitalizat ion stays were 8-29 days (11.3 days on average). Conclusion The clinical manifestations in children with measles pneu monia complicated by pneumonia mycoplasma infection were more severe, and easy to cause respiratory failure and re spiratory distress. Satisfactory curative effect can be obtained by giving macrolide antibiotics combined with the third-generation cephalosporin, intravenous immunoglobulin and methylprednisolone.